Literature DB >> 17538396

Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies.

Cristina Nanni1, Cinzia Pettinato, Valentina Ambrosini, Antonello Spinelli, Silvia Trespidi, Domenico Rubello, Adil Al-Nahhas, Roberto Franchi, Abass Alavi, Stefano Fanti.   

Abstract

BACKGROUND AND AIM: Small-animal PET is acquiring importance for pre-clinical studies. In rodents, radiotracers are usually administrated via the tail vein. This procedure can be very difficult and time-consuming as soft tissue extravasations are very frequent and tail scars can prevent repeated injections after initial failure. The aim of our study was to compare the retro-orbital (RO) versus tail vein intravenous (i.v.) administration of (18)F-FDG and (11)C-choline in mice for small-animal PET studies.
METHODS: We evaluated four healthy female ICR CD1 mice according to the following protocol. Day 1: each animal underwent an i.v. injection of 28 MBq of (11)C-choline. PET scan was performed after 10 min and 40 min. Day 2: each animal received an RO injection of 28 MBq of (11)C-choline. A PET scan was performed after 10 min and 40 min. Day 3: each animal received an i.v. injection of 28 MBq of (18)F-FDG. A PET scan was performed after 60 min and 120 min. Day 4: each animal received an RO injection of 28 MBq of (18)F-FDG. A PET scan was performed after 60 min and 120 min. Administration and image acquisition were performed under gas anaesthesia. For FDG studies the animals fasted for 2 h and were kept asleep for 20-30 min after injection, to avoid muscular uptake. Images were reconstructed with 2-D OSEM. For each scan ROIs were drawn on liver, kidneys, lung, brain, heart brown fat and muscles, and the SUV was calculated. We finally compared choline i.v. standard acquisition to choline RO standard acquisition; choline i.v. delayed acquisition to choline RO delayed acquisition; FDG i.v. standard acquisition to FDG RO standard acquisition; FDG i.v. delayed acquisition to FDG RO delayed acquisition.
RESULTS: The RO injections for both (18)F-FDG and (11)C-choline were comparable to the intravenous injection of F-FDG for the standard and delayed acquisitions.
CONCLUSION: The RO administration in mice represents a technical advantage over intravenous administration in being an easier and faster procedure. However, its use requires high specific activity while its value in peptides and other receptor-specific radiopharmaceuticals needs further assessment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538396     DOI: 10.1097/MNM.0b013e3281fbd42b

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  20 in total

1.  Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands.

Authors:  John Virostko; Joseph Henske; Laurent Vinet; Smaragda Lamprianou; Chunhua Dai; Aramandla Radhika; Ronald M Baldwin; Mohammad S Ansari; Franz Hefti; Daniel Skovronsky; Hank F Kung; Pedro L Herrera; Todd E Peterson; Paolo Meda; Alvin C Powers
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease.

Authors:  Takuya Toyonaga; Levi M Smith; Sjoerd J Finnema; Jean-Dominique Gallezot; Mika Naganawa; Jason Bini; Tim Mulnix; Zhengxin Cai; Jim Ropchan; Yiyun Huang; Stephen M Strittmatter; Richard E Carson
Journal:  J Nucl Med       Date:  2019-05-17       Impact factor: 10.057

3.  Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.

Authors:  Kyle I Swanson; Paul A Clark; Ray R Zhang; Irawati K Kandela; Mohammed Farhoud; Jamey P Weichert; John S Kuo
Journal:  Neurosurgery       Date:  2015-02       Impact factor: 4.654

4.  A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice.

Authors:  Jan Sedlacik; Adrianne Myers; Ralf B Loeffler; Regan F Williams; Andrew M Davidoff; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2012-09-21       Impact factor: 4.813

5.  Comparison of the Intraperitoneal, Retroorbital and per Oral Routes for F-18 FDG Administration as Effective Alternatives to Intravenous Administration in Mouse Tumor Models Using Small Animal PET/CT Studies.

Authors:  Chulhan Kim; In Hye Kim; Seo-Il Kim; Young Sang Kim; Se Hun Kang; Seung Hwan Moon; Tae-Sung Kim; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-05-27

6.  Long-circulating Janus nanoparticles made by electrohydrodynamic co-jetting for systemic drug delivery applications.

Authors:  Sahar Rahmani; Carlos H Villa; Acacia F Dishman; Marika E Grabowski; Daniel C Pan; Hakan Durmaz; Asish C Misra; Laura Colón-Meléndez; Michael J Solomon; Vladimir R Muzykantov; Joerg Lahann
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

7.  Euthanasia method for mice in rapid time-course pulmonary pharmacokinetic studies.

Authors:  Adam R Schoell; Bruce R Heyde; Dana E Weir; Po-Chang Chiang; Yiding Hu; David K Tung
Journal:  J Am Assoc Lab Anim Sci       Date:  2009-09       Impact factor: 1.232

8.  Noninvasive assessment of radiation-induced renal injury in mice.

Authors:  Anis Ahmad; Junwei Shi; Saba Ansari; Jumana Afaghani; Judith Molina; Alan Pollack; Sandra Merscher; Youssef H Zeidan; Alessia Fornoni; Brian Marples
Journal:  Int J Radiat Biol       Date:  2021-03-15       Impact factor: 2.694

9.  Retro-orbital injection of FITC-dextran combined with isolectin B4 in assessing the retinal neovascularization defect.

Authors:  Jizhu Li; Yuqing Wu; Bingqian Liu; Ying Huang; Qingxiu Wu; Haichun Li; Sainan Xiao; Ying Lin; Tao Li
Journal:  BMC Ophthalmol       Date:  2021-05-11       Impact factor: 2.209

10.  Assessment of renal function in mice with unilateral ureteral obstruction using 99mTc-MAG3 dynamic scintigraphy.

Authors:  Mohammed N Tantawy; Rosie Jiang; Feng Wang; Keiko Takahashi; Todd E Peterson; Dana Zemel; Chuan-Ming Hao; Hiroki Fujita; Raymond C Harris; Christopher C Quarles; Takamune Takahashi
Journal:  BMC Nephrol       Date:  2012-12-10       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.